Tuberculosis remains one of the most consequential infectious disease burdens on the planet, yet its trajectory — and the world's readiness to bend that curve — has rarely been assessed with this level of geographic and demographic granularity. As global health funding faces unprecedented contraction, understanding exactly where TB, HIV-associated TB, and multidrug-resistant TB stood before these disruptions is not merely academic; it may define which interventions survive and which populations are abandoned.
Drawing on the Global Burden of Disease Study 2023, this systematic analysis quantifies TB mortality, morbidity, and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 through 2023. The researchers employed the Cause of Death Ensemble model integrating vital registration, surveillance, verbal autopsy, and minimally invasive tissue sampling data — a methodological combination designed to overcome the chronic underreporting that plagues high-burden, low-resource settings. Incidence, prevalence, and mortality were simultaneously modeled by age and sex using DisMod-MR 2.1, with stratification by HIV co-infection and drug-resistance status. Risk factor contributions — alcohol use, smoking, and elevated fasting plasma glucose — were quantified through comparative risk assessment population attributable fractions, allowing causal attribution beyond mere correlation.
The analytical architecture here is rigorous enough to command serious attention, but context is essential. The WHO End TB Strategy targets — 95% mortality reduction and 90% incidence reduction between 2015 and 2035 — were already widely regarded as aspirational before COVID-19 reversed years of hard-won progress. GBD analyses of this scale are not clinical trials; they are epidemiological observational syntheses that depend heavily on data quality heterogeneity across regions. MDR-TB estimates carry particular uncertainty given inconsistent laboratory surveillance in sub-Saharan Africa and parts of Southeast Asia. Still, the inclusion of HIV stratification adds critical mechanistic nuance: HIV-positive individuals face fundamentally different TB biology, treatment requirements, and mortality trajectories. For health-conscious adults and public health planners alike, this study serves as a sobering baseline — a pre-disruption snapshot that will prove indispensable for measuring what the coming funding retrenchment actually costs in lives.